What science tells us about the health risks of Roundup

Key Concepts

• Glyphosate: The active chemical ingredient in the herbicide Roundup.
• Non-Hodgkin’s Lymphoma (NHL): A type of blood cancer linked to glyphosate exposure.
• IARC (International Agency for Research on Cancer): The organization that classified glyphosate as a "probable human carcinogen" in 2015.
• Regulatory Reliance: The practice of government agencies (like the EPA) basing safety assessments on data provided by manufacturers.
• Research Retraction: The invalidation of scientific papers due to ethical concerns or misconduct, which undermines previous safety claims.

---

1. Overview of the Supreme Court Ruling

The U.S. Supreme Court issued a 7-2 ruling in favor of the manufacturer of Roundup (Bayer/Monsanto). This decision overturns a jury award granted to a plaintiff who claimed that over two decades of exposure to the herbicide caused his non-Hodgkin’s lymphoma. This ruling is expected to have a significant impact on thousands of pending lawsuits across the United States, potentially limiting the manufacturer's liability.

2. Scientific Evidence and Health Risks

Dr. Shadi Nabhan, a medical oncologist and expert witness in Monsanto trials, highlights the evolution of scientific understanding regarding Roundup:

• Carcinogenicity: While Roundup has been used on over 300 million acres of U.S. farmland since the 1970s, modern research suggests a link between glyphosate and non-Hodgkin’s lymphoma.
• IARC Classification: In 2015, the IARC categorized glyphosate as a "probable human carcinogen," basing this conclusion on peer-reviewed literature, animal toxicology studies, and epidemiological data.
• The "Tobacco" Analogy: Dr. Nabhan draws a parallel to the history of tobacco, noting that society once considered smoking safe and even promoted it via medical professionals. He argues that it is a "nihilistic approach" to ignore emerging evidence of harm simply because previous assessments deemed a product safe.

3. Regulatory Framework and Data Integrity

A critical point of discussion is the reliance of the Environmental Protection Agency (EPA) on manufacturer-supplied data:

• Data Evolution: Dr. Nabhan explains that regulatory bodies often rely on the evidence available at the time of review. However, as science evolves, older data may be proven inaccurate or biased.
• The Williams et al. Retraction: A pivotal piece of evidence cited by the EPA and industry proponents to claim Roundup is safe—a paper authored by Williams and colleagues—was recently retracted due to research misconduct and ethical concerns.
• Litigation as a Catalyst: Dr. Nabhan notes that the retraction of this influential paper only occurred because of the scrutiny brought about by the Monsanto trials, which forced the disclosure of internal data and research flaws.

4. Perspectives on the Ruling

• Bayer’s Stance: In a statement, Bayer characterized the Supreme Court decision as a victory for "science, farmers, and industries" that require regulatory clarity. They argue the ruling will help contain the decade-long litigation cycle.
• Medical/Scientific Perspective: Dr. Nabhan emphasizes that from a clinical standpoint, the priority should be identifying the causes of cancer. He argues that if a compound is potentially causing harm to the public, there is a moral obligation to restrict its availability, regardless of the legal outcomes.

5. Synthesis and Conclusion

The Supreme Court ruling represents a significant legal victory for Bayer, likely curbing the wave of litigation regarding Roundup’s health impacts. However, the scientific discourse remains contentious. The core conflict lies between regulatory reliance on historical, manufacturer-provided data and the growing body of independent research suggesting a link between glyphosate and cancer. The retraction of key studies previously used to defend the product’s safety highlights the necessity of continuous scientific re-evaluation and the limitations of relying on static regulatory approvals in the face of evolving medical evidence.